Advancing Oligonucleotide & Peptide Therapeutics from Clinical R&D to Manufacturing in Asia
23 - 24 March 2027
Sands Expo & Convention Centre, Singapore
Part of Biopharma APAC Confex 2027
Co-located Events
.png)
.png)
.png)
.png)
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
EXHIBITOR
Media & Publicity
CONFERENCE AGENDA
Day 2
8:50
IMAPAC’s Opening Remarks
8:55
Chairman’s Welcome Address
Clinical Development & Regulatory Excellence
9:00
FDA & EMA Regulatory Readiness for Oligonucleotide & Peptide Therapeutics: From Early Development to Global Approval
- Navigating regulatory expectations for novel oligonucleotide and peptide modalities
- Designing clinical development strategies that support regulatory decision-making
- Addressing evidence requirements for novel mechanisms and emerging modalities
- Building regulatory strategies across the U.S., Europe and APAC
9:25
From First-in-Human to Approval: De-Risking Clinical Development for Oligos & Peptides
- Designing efficient FIH and early-phase trials for novel oligonucleotide and peptide modalities.
- Translating preclinical PK/PD, biodistribution and toxicology into dose selection and escalation strategies.
- Identifying meaningful biomarkers and clinical endpoints to demonstrate early proof of mechanism and efficacy.
- Building regulatory evidence packages that support faster progression from Phase I through pivotal development.
Reserved for Solution Provider
9:40
Dose Matters: Optimising Exposure, Target Engagement & Therapeutic Window in Oligo and Peptide Trials
- Translating tissue exposure and target engagement into rational clinical dose selection.
- Applying PK/PD modelling to understand dose-response relationships and therapeutic windows.
- Managing prolonged pharmacological effects and complex dosing intervals in oligonucleotide programmes.
- Integrating emerging clinical data to optimise dose and regimen ahead of pivotal development.
10:05
From Accelerated Approval to Global Launch: Late-Stage Development & Lifecycle Strategy for Oligos and Peptides
- Designing pivotal programmes around meaningful clinical endpoints and regulatory expectations.
- Establishing confirmatory evidence strategies for accelerated or conditional approval pathways.
- Integrating clinical, CMC and regulatory readiness as programmes move toward commercialisation.
- Planning post-marketing commitments, real-world evidence and lifecycle expansion into new indications.
10:30
Morning Break, Exhibition Viewing & 1-1 Networking
Manufacturing, CMC & Commercial Scale-Up
11:15
Tech Transfer Without the Turbulence: Moving Oligo & Peptide Processes into GMP Manufacturing
- Defining the critical process and analytical knowledge required for successful technology transfer
- Bridging gaps between process development, analytical, manufacturing, quality and external CDMO teams
- Establishing comparability when processes, equipment or manufacturing sites change
- Using risk-based transfer strategies to shorten timelines while protecting product quality and supply
11:40
Scaling the Chemistry: Optimising SPPS & Oligonucleotide Synthesis for Cost, Yield and Throughput
- Overcoming scale limitations in solid-phase peptide and oligonucleotide synthesis
- Optimising coupling efficiency, reagent consumption, cycle times and resin/support utilisation
- Reducing solvent intensity, waste generation and cost of goods at commercial volumes
- Evaluating where liquid-phase, hybrid and alternative synthesis technologies can outperform conventional approaches
Reserved for Solution Provider
11:55
Breaking the Solid-Phase Ceiling: Enzymatic, Hybrid & Next-Generation Manufacturing for Oligos and Peptides
- Assessing where enzymatic and hybrid synthesis can overcome conventional solid-phase limitations
- Comparing scalability, selectivity, productivity, cost and environmental footprint
- Addressing new CMC and regulatory considerations introduced by alternative manufacturing technologies
- Defining what is required to transition emerging synthesis platforms from proof-of-concept to GMP and commercial production
12:20
Lunch, Exhibition Viewing, Poster Presentations & 1-1 Networking
Quality, Analytics & Regulatory Innovation
2:05
From Development to GMP: Building Phase-Appropriate Analytical Control Strategies That Scale
- Designing analytical methods early with commercial scalability and GMP readiness in mind
- Defining CQAs and translating them into robust release and in-process controls
- Moving methods from development laboratories into QC without losing robustness
- Aligning analytical development, process development, QC and CMC teams to reduce late-stage surprises
2:30
AI-Powered Analytical Development: Can Automation Accelerate Release of Complex Therapeutics?
- Applying AI and machine learning to analytical data interpretation
- Automating data review while maintaining human oversight
- Strengthening data integrity and traceability
- Moving toward faster, risk-based QC and batch release
Reserved for Solution Provider
2:45
Beyond the Main Peak: Advanced Impurity Profiling & Control Strategies for Oligos and Peptides
- Identifying process-, product- and degradation-related impurities across increasingly complex molecules
- Applying LC-MS/HRMS and orthogonal analytical techniques to resolve closely related species
- Linking impurity origin and formation pathways to CQAs and process controls
- Establishing scientifically justified impurity thresholds and specifications for regulatory submissions
3:10
Analytics for the Next Generation: Characterising Conjugated, Modified & Non-Canonical Oligos and Peptides
- Tackling heterogeneity introduced by conjugation, chemical modifications and novel structures
- Combining chromatographic, mass spectrometric and orthogonal methods for deeper characterization
- Defining molecule-specific CQAs for increasingly complex modalities
- Developing platform analytical approaches while retaining flexibility for modality-specific risks
3:35
Afternoon Tea, Exhibition Viewing & 1-1 Networking
Convergence of RNA, Peptides & Next-Generation Therapeutics
4:20
Beyond ADCs: APCs & RDCs for the Next Wave of Precision Therapeutics
- Advancing APCs and RDCs as emerging targeted therapeutic platforms
- Expanding applications beyond traditional oncology
- Optimising targeting, payload design and therapeutic precision
- Translating novel conjugates from platform innovation to the clinic
4:25
From Breakthrough Platform to Global Product: What Will It Take to Commercialize Next-Generation Therapeutics?
- Identifying technologies with the strongest potential to reach commercial scale
- Overcoming delivery, CMC, regulatory and market-access barriers
- Building global development and manufacturing strategies from Asia
- Turning platform innovation into sustainable product pipelines
Reserved for Solution Provider
4:40
AI-Enabled mRNA Therapeutics: From Precision Design to Clinical Translation
- Applying AI and in silico approaches to optimise therapeutic mRNA design
- Integrating computational prediction with biological and immunological validation
- Advancing precision mRNA approaches for therapeutic applications
- Translating next-generation mRNA platforms into clinical-stage programmes
Wonil Kim
CSO, Aston Sci 
5:05
Accelerating RNA Therapeutic Discovery: High-Throughput Screening, Design & Safety
- High-throughput screening strategies for RNA therapeutic discovery
- Compound design and optimisation to accelerate candidate selection
- Integrating in vitro safety assessment during early lead development
- Improving the quality and confidence of preclinical RNA candidates
Dr. Pratik Dave
Senior Scientist, Roche 
5:30
Asia’s Next Wave of RNA & Peptide Innovation - What Will Win the Race to Market?
Questions:
- Which therapeutic modality will define the next phase of RNA and peptide innovation?
- Where should industry focus next: delivery, clinical validation, manufacturing or regulatory strategy?
- Can Asia become the global launchpad for next-generation therapeutics rather than simply a development and manufacturing hub?
6:15
Chairman’s Closing Remarks
6:20
End of day 2 conference
By Profile
By Job Title
By Geography
10%
Europe & USA
15%
China & Taiwan
20%
South Korea
10%
Japan
15%
Hong Kong, India & Philippines
30%
Indonesia, Malaysia, Singapore & Thailand
10%
Europe & USA
15%
China & Taiwan
20%
South Korea
10%
Japan
15%
Hong Kong, India & Philippines
30%
Indonesia, Malaysia, Singapore & Thailand
Our Past Partners
.png)
%20(1)%20(1).png)
%20Logo.png)
